24
Aug
Aug
What published research reports about TB-500 and thymosin beta-4 safety, including the one human safety study, the negative findings, and the gaps nobody has filled.
24
Aug
Aug
A randomized human trial of thymosin beta-4 after a heart attack was null overall, with a signal only in an early-dosing subgroup. Both halves explained.
24
Aug
Aug
Two published studies found thymosin beta 4 weakened the gut lining in rats and mice. Here is what they measured, what they did not test, and why we publish it.
24
Aug
Aug
The eye is where thymosin beta-4 has the most human data. A plain-language look at the dry eye trials, the p=0.0656 Phase III, and what is still missing.
24
Aug
Aug
The published thymosin beta-4 study figures, the animal numbers, and the honest answer for TB-500 itself: no human dose has ever been published.
24
Aug
Aug
One published animal study gave TB-500 itself and measured brain outcomes. Here is what it reported, the result it did not find, and what is still missing.
23
Aug
Aug
What amounts has BPC-157 research actually used? The published animal figures, the human-tissue concentrations, and the honest answer on human dosing: none is published.
23
Aug
Aug
BPC-157 is studied in animal, cell, and tissue models of tendon, gut, blood vessel, nerve, and wound repair. A plain-language map of every research area.
23
Aug
Aug
A plain-language review of published BPC-157 wound research: a burn model, fistula repair in rats, and growth-factor comparisons. Animal and lab data only.
23
Aug
Aug
BPC-157 and KPV are studied for different things, and both appear in gut research. A plain-language look at what the published work covers and what it does not.